254 related articles for article (PubMed ID: 8073671)
1. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide.
Kolaric K; Bradamante V; Cervek J; Cieslinska A; Cisarz-Filipcak E; Denisov LE; Donat D; Drosik K; Gershanovic M; Hudziec P
Oncology; 1995; 52(3):251-5. PubMed ID: 7715910
[TBL] [Abstract][Full Text] [Related]
3. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
4. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
[TBL] [Abstract][Full Text] [Related]
5. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
Jurga L; Misurová E; Vancík J
Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
[No Abstract] [Full Text] [Related]
8. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity.
Martin M; Lluch A; Ojeda B; Barnabas A; Colomer R; Massuti B; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-26-S17-30. PubMed ID: 9374088
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
12. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
[TBL] [Abstract][Full Text] [Related]
14. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin.
de Bree E; van Ruth S; Schotborgh CE; Baas P; Zoetmulder FA
Ann Surg Oncol; 2007 Oct; 14(10):3019-26. PubMed ID: 17638057
[TBL] [Abstract][Full Text] [Related]
15. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
16. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
[TBL] [Abstract][Full Text] [Related]
17. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Bustová I
Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
[TBL] [Abstract][Full Text] [Related]
18. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
20. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.
Abu-Khalaf MM; Juneja V; Chung GG; DiGiovanna MP; Sipples R; McGurk M; Zelterman D; Haffty B; Reiss M; Wackers FJ; Lee FA; Burtness BA
Breast Cancer Res Treat; 2007 Sep; 104(3):341-9. PubMed ID: 17051423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]